Lung Cancer Panel 4 [EGFR,ALK1,ROS1,MET,PD L1] Test
Short Name: Lung Cancer Panel 4
Also known as: Lung Cancer Mutation Panel, EGFR ALK ROS1 MET PD-L1 Panel
Lung Cancer Panel 4 [EGFR,ALK1,ROS1,MET,PD L1] Test test available at DNA Labs India for ₹30,000. Uses FISH, Sanger Sequencing, Immunohistochemistry (IHC) for PD-L1 on Tumor tissue (paraffin embedded block) samples. Results in Results are typically available within 5-7 working days after the laboratory receives the sample. You will be notified via SMS/email when the report is ready.. Free home collection in 300+ cities across India.
🩺 Medically Reviewed By
Dr Pasupathy Arumugam
Consultant Pathologist · Reg: 21521
Last reviewed: September 7, 2026
Overview
The purpose of this test is to detect specific genetic alterations in the EGFR, ALK1, ROS1, MET genes and PD-L1 expression in lung tumor tissue. These biomarkers guide the use of targeted therapies (e.g., tyrosine kinase inhibitors) and immunotherapies (e.g., checkpoint inhibitors), enabling personalized treatment decisions for lung cancer patients.
- Test Code
- 6120
- CPT Code
- 81445
- ICD Code
- C34.90
- Price
- ₹30,000
- Sample Type
- Tumor tissue (paraffin embedded block)
- Result Time
- Results are typically available within 5-7 working days after the laboratory receives the sample. You will be notified via SMS/email when the report is ready.
- Fasting Required
- No
- Method
- FISH, Sanger Sequencing, Immunohistochemistry (IHC) for PD-L1
Sample Collection
No special preparation required. A doctor's prescription is mandatory. Inform your doctor about any ongoing medications or treatments.
Method: Biopsy or surgical resection
Laboratory Analysis
The sample is collected via biopsy or surgical resection by a qualified healthcare professional. The procedure may cause minor discomfort but is generally safe.
Report Delivery
The tissue sample is sent to the laboratory. You can resume normal activities immediately. Results are typically available in 5-7 days.
Timeline: Results are typically available within 5-7 working days after the laboratory receives the sample. You will be notified via SMS/email when the report is ready.
Patient Instructions
About This Test
Who Should Get This Test
The purpose of this test is to detect specific genetic alterations in the EGFR, ALK1, ROS1, MET genes and PD-L1 expression in lung tumor tissue. These biomarkers guide the use of targeted therapies (e.g., tyrosine kinase inhibitors) and immunotherapies (e.g., checkpoint inhibitors), enabling personalized treatment decisions for lung cancer patients.
How to Prepare
- Tumor tissue block or slides must be sent in a cool pack
- Ensure the sample is properly labeled with patient details
- Avoid freezing the sample
- Include a copy of the pathology report if available
Doctor's Notes
Reviewed by Dr Pasupathy Arumugam — MBBS, MD (Pathology) · Reg. No. 21521
"This panel is essential for guiding targeted therapy in non-small cell lung cancer. Identifying actionable mutations in EGFR, ALK, ROS1, MET, and PD-L1 expression helps select the most effective treatment, improving outcomes and avoiding unnecessary toxicity."
Last medically reviewed: September 7, 2026
Test Parameters & Specifications
Sample Stability
- Insufficient tumor tissue (<20% tumor cells)
- Sample with extensive necrosis
- Improperly labeled or unlabeled sample
- Sample not accompanied by prescription
Understanding Your Results
Positive for exon 19 deletion
Likely response to EGFR TKIs (e.g., osimertinib, erlotinib)
Positive for rearrangement
Eligible for ALK inhibitors (e.g., crizotinib, alectinib)
Positive for rearrangement
Eligible for ROS1 inhibitors (e.g., crizotinib, entrectinib)
Amplification or exon 14 skipping
Consider MET inhibitors (e.g., capmatinib, tepotinib)
TPS ≥50%
High likelihood of response to PD-1/PD-L1 inhibitors (e.g., pembrolizumab)
Consult your oncologist if you have been diagnosed with lung cancer and are considering targeted therapy or immunotherapy. Also, consult if you experience new or worsening symptoms such as persistent cough, chest pain, or unexplained weight loss.
Limitations
- ⚠Tumor heterogeneity may cause sampling bias
- ⚠Sanger sequencing has limited sensitivity for low allele frequency mutations
- ⚠FISH may miss some rare rearrangements
- ⚠PD-L1 IHC is semi-quantitative and subject to inter-observer variability
Risks & Considerations
- ●Minor bleeding or infection at biopsy site
- ●Pneumothorax (if lung biopsy)
- ●Allergic reaction to anesthesia (rare)
Interfering Factors
- ●Inadequate tumor content (<20%) in sample
- ●Decalcification of bone specimens may degrade DNA
- ●Necrotic tissue may yield false negatives
- ●Recent chemotherapy or radiation may affect biomarker expression
Compare With Similar Tests
| Test | Lung Cancer Panel 4 [EGFR,ALK1,ROS1,MET,PD L1] | Lung Cancer Panel 1 (EGFR, ALK) | Lung Cancer Panel 2 (EGFR, ALK, ROS1) | Lung Cancer Panel 3 (EGFR, ALK, ROS1, PD-L1) | Lung Cancer Panel 4 (EGFR, ALK, ROS1, MET, PD-L1) |
|---|---|---|---|---|---|
| Comparison | Lung Cancer Panel 4 [EGFR,ALK1,ROS1,MET,PD L1] |
Frequently Asked Questions
What is the cost of the Lung Cancer Panel 4 test?
What sample is required for this test?
Do I need to fast before the test?
How long does it take to get results?
Is home sample collection available?
What genes are analyzed in this panel?
Who should get this test?
Is a doctor's prescription required?
What is the turnaround time for reports?
Can this test be done on a blood sample?
What is the significance of PD-L1 testing?
Are there any risks associated with the biopsy?
Related Tests
B-Cell Rearrangement Detection Test
₹22,000Acute Lymphoblastic Leukemia (ALL) Cytogenetics Panel Test
₹20,000Epstein-Barr Virus Early RNA (EBER-ISH) In-Situ-Hybridization Test
₹6,000OncoPro NCCN Lung Cancer Panel with PD-L1 Test
₹140,400Acute Myeloid Leukemia (AML) Cytogenetics Panel Test
₹23,000AML ETO t(8;21) Gene Rearrangement PCR Qualitative Test
₹6,000Reference Laboratory Services
We serve as a reference laboratory for hospitals and clinics across India. Send samples from your facility with same-day pickup, priority processing, and results delivered through our online portal. Competitive institutional pricing available.
Your Data Privacy
Your medical data is protected under Indian law.
✓ Stored in India: All patient records are stored on servers located in India. No data is transferred outside the country.
✓ DPDP Act Compliant: Under the Digital Personal Data Protection Act 2023, you can request deletion of your records at any time by contacting support.
Book Your Test
Enter your details and we'll connect you within 15 minutes.